Gilead Sciences (GILD) return on equity (ROE)

Return on equity · fiscal 2025
37.5%

Gilead Sciences (GILD) earned a return on equity of 37.5% in fiscal 2025 (the year ended December 31, 2025). That is 35.0 percentage points higher than the 2.5% of fiscal 2024. Figures as of 18 Nov 2026, 05:04 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Return on equity, fiscal 2025
37.5%
Change on fiscal 2024
+35.0 pts
Highest on record
97.7%fiscal 2015
Lowest on record
0.7%fiscal 2020
Fiscal years on record
192007–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.

Gilead Sciences return on equity (ROE), in more detail

Across the 19 fiscal years on record (2007–2025), the highest was 97.7% in fiscal 2015 and the lowest 0.7% in fiscal 2020. The fiscal 2025 figure is higher than in 56% of the 18 earlier fiscal years on record, whose median is 28.7%.

History · 19 fiscal years

Return on equity by fiscal year

Gilead Sciences return on equity (ROE), year by year

Gilead Sciences (GILD) return on equity (ROE) by fiscal year
Fiscal yearReturn on equityChangeYear ended
202537.5% 35.0 pts up
20242.5% 22.3 pts down
202324.8% 3.2 pts up
202221.6% 7.9 pts down
202129.5% 28.9 pts up
20200.7% 23.2 pts down
201923.9% 1.6 pts down
201825.5% 2.9 pts up
201722.6% 48.8 pts down
201671.5% 26.2 pts down
201597.7% 19.3 pts up
201478.4% 51.4 pts up
201327.0% 0.8 pts down
201227.9% 13.7 pts down
201141.6% 7.9 pts down
201049.5% 8.1 pts up
200941.4% 4.9 pts down
200846.3% 4.1 pts up
200742.2%—

Change is on the fiscal year before, in percentage points; a dash means that year is not on record. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

How to read it

It is the profit earned on the owners' capital — above about 15% is strong, though heavy debt or large buybacks can inflate it.

Return on equity at health care companies of similar size

Return on equity of Gilead Sciences and comparable companies
CompanyReturn on equityFiscal year
Thermo Fisher Scientific TMO12.6%2025
Amgen AMGN89.1%2025
Gilead Sciences GILD37.5%2025
Abbott Laboratories ABT12.5%2025
Novo Nordisk NVO52.8%2025
Pfizer PFE9.0%2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on GILD

Gilead Sciences, figure by figure

Gilead Sciences (GILD) overview: price, valuation and scorecardAll health care companies by market value

Gilead Sciences return on equity (ROE): questions and answers

What is Gilead Sciences's return on equity?

Gilead Sciences (GILD) earned a return on equity of 37.5% in fiscal 2025 (the year ended December 31, 2025). That is 35.0 percentage points higher than the 2.5% of fiscal 2024.

Is Gilead Sciences's return on equity high or low compared with its own history?

The fiscal 2025 figure is higher than in 56% of the 18 earlier fiscal years on record, whose median is 28.7%.

What are the highest and lowest return on equity figures on record for Gilead Sciences?

Across the 19 fiscal years on record (2007–2025), the highest was 97.7% in fiscal 2015 and the lowest 0.7% in fiscal 2020.

How is Gilead Sciences's return on equity calculated?

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Gilead Sciences (GILD) return on equity (ROE)”, data as of 18 November 2026. https://funkfolio.com/stock/GILD/roe

Underlying data: the company's filings with the SEC and Yahoo Finance.